$SRCGF: Homeland Nickel Completes Minority Shareholder

New Post Public Reply Private Reply Replies (0) Message Board
Lee Adams
128
$SRCGF: Homeland Nickel Completes Minority Shareholder Acquisition

Toronto, Ontario –TheNewswire -November 6, 2024 – Homeland Nickel Inc.(“Homeland Nickel” or the “Company”) (TSX-V: SHL, OTC: SRCGF) is pleased to announce it has closed the previously announced acquisition of an additional 18.5% interest in Homeland Nickel Corporation (“HNC”), the U.S. subsidiary holding the rights to the mining claims at the Company’s Cleopatra and Red Flat nickel laterite properties.

During June and July of 2024, Homeland Nickel successfully negotiated with six of the seven minority shareholders of HNC to acquire 85,990 common shares in the capital of HNC (the “HNC Shares”), representing an 18.5% interest in HNC. Following the acquisition, Homeland Nickel’s ownership of HNC increased to 98.5% (from the previous 80%). In exchange for the HNC Shares, the Company issued to the shareholders of HNC a total of 3,439,600 common shares of Homeland Nickel (the “Consideration Shares”) at an issue price of $0.05 per share. The Consideration Shares are subject to a statutory hold period of four months and one day in accordance with applicable securities laws. The Company was also able to obtain a full release from all parties.

President and CEO Steve Balch stated that “We thank the minority shareholders of what was formerly Red Flat Nickel Corp. We have provided liquidity to these individuals in the form of Homeland Nickel common shares in return for their interest and a full release. Going forward we have no debt on these properties, and we now own a 98.5% interest in Cleopatra and Red Flat, up from the previous 80%. We will work to make that interest 100% over time.”

The Acquisition constituted an “Expedited Acquisition” in accordance with TSX Venture Exchange Policy 5.3 –Acquisitions and Dispositions of Non-Cash Assetsand remains subject to final approval by the TSX Venture Exchange.

About Homeland Nickel

Homeland Nickel is a Canadian-based mineral exploration company focused on critical metal resources with nickel projects in Oregon, United States and copper projects in Newfoundland, Canada. The Company also holds a significant portfolio of mining securities including 2.95 million shares of Canada Nickel Company Inc. (TSX-V:CNC), 9.96 million shares of Noble Mineral Exploration Inc. (TSX-V:NOB), 13,.8 million shares of Benton Resources Inc. (TSX-V:BEX) and 2.7 million shares of Magna Terra Minerals Inc. (TSX-V:MTT). Homeland Nickel’s common shares trade on the TSX Venture Exchange under the symbol “SHL”. More detailed information can be found on the Company’s website at:

http://www.homelandnickel.com

Cautionary Statement

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

This news release contains statements that constitute “forward-looking statements”. Forward-looking statements are statements that are not historical facts and include, but are not limited to, disclosure regarding possible events, that are based on assumptions and courses of action, and in certain cases, can be identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur, or the negative forms of any of these words and other similar expressions. Forward-looking statements include statements related to future plans for the Company, and other forward-looking information. Forward-looking statements are based on various assumptions including with respect to the anticipated actions ofsecurities regulators, stock exchanges, and government entities, management plans and timelines, as well as results of operations, performance, business prospects and opportunities. Although the forward-looking statements contained in this news release are based upon what the management of the Company believes are reasonable assumptions on the date of this news release, such assumptions may prove to be incorrect. Forward-looking statements involve known and unknown risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. A number of factors could cause actual results, performance or achievements to differ materially from the results discussed in the forward-looking statements, including, but not limited to: an inability to develop and successfully implement exploration strategies; general business, economic, competitive, political and social uncertainties; the lack of available capital; impact of the evolving situation in Ukraine on the business of the Company; and other risks detailed from time-to-time in the Company’s ongoing filings with securities regulatory authorities, which filings can be found at www.sedarplus.ca. The Company cannot assure readers that actual results will be consistent with these forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements in this press release. These forward-looking statements are made as of the date of this news release and the Company disclaims any intent or obligation to update any forward-looking statement, whether because of new information, future events or otherwise, unless otherwise required by law.

Contact

Stephen Balch, President & CEO

Phone: 905-407-9586

Email: steve@beci.ca
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ribo Advances Lipid Disorder Strategy with SR122 Trial

Updated Category News Views 114

Ribo's New Chapter in Lipid Disorders For those keeping tabs on the cutting-edge of lipid research, Ribo’s latest maneuver isn't one to skim over. The company, hailing from both Suzhou and Sweden, just moved forward by submitting its Phase I Clinical Trial Application in Europe for a fascinating compound: SR122. This development isn’t just another filing; it marks a...

Continue Reading
Quest Diagnostics at Jefferies Conference: What’s Next?

Updated Category News Views 65

Quest Diagnostics Set for the Spotlight in London You're sipping your morning coffee when you hear that Quest Diagnostics (NYSE: DGX) is gearing up for a fireside chat in the UK's capital. Now, this isn't a random chit-chat we're talking about. Sam Samad, the man handling the books as their CFO, will be chatting it up at the Jefferies Global Healthcare Conference on...

Continue Reading
Burtch Works Joins Databricks: Fueling AI Success

Updated Category News Views 20

Game-Changer for AI Talent Market First off, let me tell you, in this data-driven world, finding solid AI talent is like hitting the jackpot. Burtch Works teaming up with Databricks? That's like leaping into a goldmine fully prepared. We're talking about forward-deployed engineers and specialized AI talent coming straight to your door. Closing the Impossible Talent Gap...

Continue Reading
Bimbo Bakeries Teamsters Gear Up for Strike in NJ

Updated Category News Views 102

A Brewing Storm at Bimbo Bakeries The morning air in East Brunswick fills with more than just the scent of fresh bread; there’s a tension you can slice through with a butter knife. Unwavering and fired-up, over 90 workers at Bimbo Bakeries have thrown their hats into the ring, ready to strike to protect something as sacred as the dough they churn—Teamsters' health...

Continue Reading
Zura Bio Faces Tough Road After Trial Failure

Updated Category News Views 155

Investor Dilemma: ZURA Takes a Nosedive November 9, 2026, wasn't a day to remember for anyone holding shares in Zura Bio. If ever there's a classic lesson in biotech investing's volatility, this is it: shares of Zura Biotech (NASDAQ:ZURA) cratered by about 72% after news broke that their much-hyped Phase 2 TibuSHIELD trial for tibulizumab hit the skids. For a company that...

Continue Reading
Gold.com Faces Fiduciary Investigation by Levi & Korsinsky

Updated Category News Views 56

Gold.com in Hot Water: What Shareholders Need to Know You ever wonder how firms like Gold.com find themselves in sticky situations before the ink's dry on the quarterly report? Well, strap in because Levi & Korsinsky, LLP is poking around to see if some officers and directors over there have taken a stroll down Breach Avenue. And let me tell you, if you're holding onto...

Continue Reading
Cloud Software Group's $2B Debt Offer Wraps Up

Updated Category News Views 115

Sizing Up Cloud Software Group’s Recent Maneuver Whoever thought navigating debt was a dull spectacle hasn’t kept up with Cloud Software Group's recent financial theatrics. With a $2 billion cap on the table, their cash tender offer for 9.00% Senior Secured Second Lien Notes due 2029 didn’t just happen; it paraded onto the financial stage and left a noteworthy...

Continue Reading
Inner City Visions Celebrates Two Decades of Impact

Updated Category News Views 126

Alfred Lomas' Transformation Fuels Lasting Change Once upon a time, Alfred Lomas was known as a brawler in the rough patches of South L.A., running with gangs and entangled in violence. But the story flipped, and instead of leaning into chaos, Lomas leaned into hope. That personal turnaround isn't just a headline—it's the crux behind Inner City Visions (ICV), the...

Continue Reading
Mesh Security Bolsters Team with Five Cybersecurity Experts

Updated Category News Views 252

New Blood in Cybersecurity: Mesh's Strategic Moves Ever felt like the cybersecurity world is in a constant game of catch-up? You're not wrong. In today's digital battleground, companies don't just need more tools—they need collective wisdom to bind it all together. And it seems like Mesh Security just caught onto that notion, stacking their deck with five new...

Continue Reading
Charitable Giving Turbocharges E-commerce Conversion Rates

Updated Category News Views 50

Charitable Giving: The Secret Sauce for E-commerce Success In an e-commerce arena teeming with bland sameness, charitable giving is proving to be a game-changing hook. That's right—brands partnering with Change and DailyKarma have found a magic formula where customers flourish and causes benefit. With over $7.4 million in donations spread across more than 3 million...

Continue Reading

Top 5 Most Recently Viewed Articles

Get A Drip Names New CMO Amid Longevity Boom

Updated Category News Views 21

So, here's a curveball in the health gig—longevity's caught a second wind. And who's riding the wave? Get A Drip, the UK hotshot in the wellness league. They've just snagged Dr. Luke Pratsides as their new Chief Medical Officer. Imagine adding a sharp arrow to the quiver at a time when folks are head-over-heels for living longer and staying healthier. Longevity at the...

Continue Reading
Class Action Lawsuit Alert for Marex Group Investors - Act Now!

Updated Category News Views 157

Attention Investors: Marex Group Class Action Lawsuit Announced Investors in Marex Group plc (NASDAQ: MRX) should take note of an important development. A class action lawsuit has been initiated against Marex on behalf of those who purchased shares during the specified time frame. This legal action addresses serious allegations of financial misconduct, leading to...

Continue Reading
Navigating Political Challenges: Macron's Strategy with Barnier

Updated Category News Views 69

Understanding Barnier's New Role in French Politics After navigating the intricate Brexit negotiations, Michel Barnier has now stepped into a demanding role as Prime Minister. This position is crucial for tackling the urgent challenges within France's divided political environment. Challenges Awaiting Barnier Emmanuel Macron selected Barnier to steer his government...

Continue Reading
Verona Pharma Receives Shareholder Approval for Merck Deal

Updated Category News Views 211

Verona Pharma's Shareholders Greenlight Merck Acquisition In a significant step for Verona Pharma, shareholders have given the green light for the proposed acquisition by Merck & Co., marking a pivotal moment in the biopharmaceutical company's journey. Verona Pharma plc, listed on Nasdaq under the ticker VRNA, focuses on developing innovative therapies for chronic...

Continue Reading
2024 Luxury Resale Insights from The RealReal

Updated Category News Views 818

Insights from The RealReal's 2024 Luxury Resale Report Consumers Lead the Charge, Redefining Trends and Investing in Lasting Value The RealReal, the largest online marketplace for authenticated resale luxury goods, has unveiled its seventh annual 2024 Luxury Resale Report. This extensive report draws on 13 years of data to analyze the current state of luxury resale,...

Continue Reading